Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry X-ray apparatus & tubes
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHEK
CUSIPN/A
Phone972-4830-3401
Debt
Debt-to-Equity RatioN/A
Current Ratio2.95
Quick Ratio2.95
Price-To-Earnings
Trailing P/E Ratio-0.60
Forward P/E Ratio-1.38
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.68 per share
Price / Book1.04
Profitability
EPS (Most Recent Fiscal Year)($6.42)
Net Income$-9,770,000.00
Net MarginsN/A
Return on Equity-157.18%
Return on Assets-112.62%
Miscellaneous
Employees55
Outstanding Shares1,600,000
Market Cap$0.00
Check Cap (NASDAQ:CHEK) Frequently Asked Questions
What is Check Cap's stock symbol?
Check Cap trades on the NASDAQ under the ticker symbol "CHEK."
When did Check Cap's stock split? How did Check Cap's stock split work?
Check Cap's stock reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 3rd 2018. An investor that had 100 shares of Check Cap stock prior to the reverse split would have 8 shares after the split.
How were Check Cap's earnings last quarter?
Check Cap Ltd (NASDAQ:CHEK) posted its quarterly earnings data on Thursday, May, 17th. The medical research company reported ($1.27) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.68) by $0.41. View Check Cap's Earnings History.
When is Check Cap's next earnings date?
What price target have analysts set for CHEK?
2 equities research analysts have issued 12 month target prices for Check Cap's shares. Their predictions range from $14.00 to $60.00. On average, they anticipate Check Cap's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 871.1% from the stock's current price. View Analyst Ratings for Check Cap.
What is the consensus analysts' recommendation for Check Cap?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check Cap in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Check Cap stock?
Here are some recent quotes from research analysts about Check Cap stock:
- 1. According to Zacks Investment Research, "Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. " (5/9/2018)
- 2. Maxim Group analysts commented, "Summary Check-Cap announced that the company has filed for the CE Mark registration of C-Scan. Sure, that is positive news. We worry that the reported 44% sensitivity" in N=45 subjects is low but we see room for that number to rise with improved software. The press release goes on to state that in the analysis for polyps, specificity was 89%". Sensitivity strongly correlated (R-squared = 0.98) to the percentage of the colon scanned. Sensitivity was 78% (p<0.05) and 100% (p<0.05) for subjects where greater than 50% and 70% of the colon was scanned, respectively. Specificity was consistent for all subjects. We conclude that for CE Mark and in Europe where the standard of care is comparable (stool test) that the data should support an approval. We also recognize however that the US standard will be much higher as the US comparison must be colonoscopy (85-90%) sensitive."" (9/27/2017)
Who are some of Check Cap's key competitors?
Some companies that are related to Check Cap include "WideCells Group PLC" (WDC), Advanced Accelerator Application (AAAP), Alchemist Mining (AMS), Altimmune (ALT), AMS (AMS), Apollo Medical (AMEH), Bayer (BAYN), BioMerieux (BMXMF), Bohai Pharmaceuticals (BOPH), Brain Resource (BRRZY), Can-Fite Biopharma (CANF), Cannabix Technologies (BLOZF), Carl Data Solutions (CRL), Circassia Pharmaceuticals (CIR) and Cosmos (COSM).
Who are Check Cap's key executives?
Check Cap's management team includes the folowing people:
- Mr. Alex Ovadia, Chief Exec. Officer (Age 56)
- Mr. William Densel, Chief Exec. Officer (Age 50)
- Dr. Yoav Kimchy, Founder and Chief Technology Officer (Age 57)
- Mr. Lior Torem, CFO & Principal Accounting Officer (Age 48)
When did Check Cap IPO?
(CHEK) raised $13 million in an initial public offering (IPO) on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager.
Has Check Cap been receiving favorable news coverage?
News headlines about CHEK stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Check Cap earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 45.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Check Cap?
Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Check Cap's stock price today?
One share of CHEK stock can currently be purchased for approximately $3.81.
How can I contact Check Cap?
Check Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972-4830-3401.
MarketBeat Community Rating for Check Cap (NASDAQ CHEK)
MarketBeat's community ratings are surveys of what our community members think about Check Cap and other stocks. Vote "Outperform" if you believe CHEK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHEK will underperform the S&P 500 over the long term. You may vote once every thirty days.
